Home » Stocks » GRAY

Graybug Vision, Inc. (GRAY)

Stock Price: $32.01 USD -2.99 (-8.54%)
Updated Jan 25, 2021 4:00 PM EST - Market closed
After-hours: $33.09 +1.08 (3.37%) Jan 25, 6:54 PM
Market Cap 734.28M
Revenue (ttm) n/a
Net Income (ttm) n/a
Shares Out 2.82M
EPS (ttm) n/a
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 25
Last Price $32.01
Previous Close $35.00
Change ($) -2.99
Change (%) -8.54%
Day's Open 34.19
Day's Range 31.42 - 34.31
Day's Volume 31,239
52-Week Range 12.71 - 35.00

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 2 weeks ago

REDWOOD CITY, Calif., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines to treat ...

GlobeNewsWire - 2 months ago

REDWOOD CITY, Calif., Nov. 16, 2020 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the t...

GlobeNewsWire - 2 months ago

REDWOOD CITY, Calif., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the t...

Seeking Alpha - 3 months ago

U.S. IPO Weekly Recap: Health And Tech Dominate The Calendar In An 11 IPO Week

Other stocks mentioned: AMST, BSY, CRSR, FCACU, GDRX, GLSI, LSF, PMVP, PRLD, ARRY
Market Watch - 4 months ago

Graybug Vision Inc.'s stock started its public life with a rally, as it opened 18.8% above its initial public offering price. The first trade was at $19.00 at 12:15 p.m.

GlobeNewsWire - 4 months ago

REDWOOD CITY, Calif., Sept. 25, 2020 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines to tre...

Market Watch - 4 months ago

Graybug Vision Inc. GRAY, +2.59% said early Friday that its upsized initial public offering priced at $16 a share, in the middle of the expected range of $15 to $17 a share.

GlobeNewsWire - 4 months ago

REDWOOD CITY, Calif., Sept. 24, 2020 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines to tre...

Seeking Alpha - 4 months ago

Graybug Vision has filed to raise $75 million from the sale of its common stock in a U.S. IPO.

About GRAY

Graybug Vision, a clinical stage biopharmaceutical company, develops medicines for the treatment of diseases of the retina and optic nerve. Its lead product candidate is GB-102, an intravitreal injection of a microparticle depot formulation of sunitinib that is in Phase I/IIa and IIb clinical trials for the treatment of wet age-related macular degeneration, as well as in Phase IIa clinical trial to treat diabetic macular edema. The company is also developing GB-103, a once-a-year formulation of GB-102, for the treatment of diabetic retinopathy;... [Read more...]

Industry
Biotechnology
IPO Date
Sep 25, 2020
CEO
Dr. Frederic Guerard Pharm.D.
Employees
29
Stock Exchange
NASDAQ
Ticker Symbol
GRAY
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 5 analysts, the average rating for Graybug Vision stock is "Strong Buy." The 12-month stock price forecast is 35.00, which is an increase of 9.34% from the latest price.

Price Target
$35.00
(9.34% upside)
Analyst Consensus: Strong Buy